# Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis

> **NCT03500367** · PHASE4 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** rapamycin

## Key facts

- **NCT ID:** NCT03500367
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2018-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03500367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03500367, "Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03500367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*